The number of deaths because of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to increase around the world, with Italy and China being the countries with the highest mortality. The main comorbidity found in these patients was hypertension: In Italy, the National Institute of Health reported such condition in 73.8% of the deceased \[[@R1]\], whereas in China it was 39.7% according to the Centers of Disease Control and Prevention (CDC), which agrees with the study by Guan *et al*. \[[@R2]\] where 35.8% of patients with a history of hypertension, were admitted to ICU or required mechanical ventilation or died.

A possible cause of this unusual association between hypertension and COVID-19, is explained as SARS-CoV-2 uses the angiotensin-converting enzyme 2 (ACE2) as a cell entry receptor, which is expressed mainly in alveolar, intestinal and renal epithelial cells, as well as in the vascular endothelium. Thus, it is proposed that the expression of ACE2 is increased in patients with hypertension because of an imbalance in the renin\--angiotensin system, increasing their susceptibility to infection and complications by SARS-CoV-2, particularly in patients on treatment with either angiotensinogen-converting enzyme (ACE) inhibitors or angiotensin II type I receptor blockers (ARBs) \[[@R3]\]. However, at the present time, there is not enough data to discontinue the use of ACE inhibitors and ARBs in patients with COVID-19, further studies are needed.

Likewise, another hypothesized causative mechanism is that in the presence of long-term hypertension, there is an inflammatory endothelial dysfunction that can lead to an increased risk of an overreacting immune response, triggering a cytokine storm in the context of a potent viral infection, such as SARS-CoV-2, especially in the elderly, where in turn immunosuppression exists, causing a more severe condition as multiple organ failure or acute respiratory distress syndrome \[[@R4]\]. The low prevalence of COVID-19 in children could be because of a better innate inflammatory response and a lower expression of ACE2 in the lower respiratory tract \[[@R5]\].

Therefore, we suggest having more careful monitoring in the management and follow-up of the elderly patient with COVID-19 and cardiovascular disease as hypertension, because of its greater probability of complications and mortality, either in the outpatient or inpatient setting; similarly, in the upcoming clinical trials that are performed with cardiotoxic drugs, such as hydroxychloroquine and azithromycin, which are currently being studied as a possible treatment for COVID-19.
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